The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

Osteoinductive, bone morphogenic protein receptor-binding peptides are disclosed. The peptides may be used to coat or infuse scaffolds for use as implants into bone for enhancing the growth, proliferation, and differentiation of mesenchymal stem cells and/or osteoblasts in the bone.

The present invention relates to a medical device to be applied to a body of a human or animal being. The medical device comprises a contact surface to contact the body of the human or animal being when the medical device is applied to the body of the human or animal being. The contact surface is covered with a soluble surface sealing. The surface sealing is composed of an organic compound.

An implantable therapy delivery device that includes a porous pouch and a cell encapsulation device configured to fit inside the porous pouch. The porous pouch may include a bio-absorbable material and/or a vascularization promotor, and the porous pouch may be packaged separately from the cell encapsulation device.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

Techniques are provided for controlling delivery of a therapeutic coating to a medical implant device. An identifier of the medical implant device may be received. It may be determined, based at least in part on the first identifier, that the first medical implant device is approved to receive the therapeutic coating. A coating applicator system may be switched from a locked state in which it is prohibited from applying the therapeutic coating to an unlocked state in which it is permitted to apply the therapeutic coating. The coating applicator system may, while in the unlocked state, apply the therapeutic coating to the first medical implant device. After the applying of the therapeutic coating, the coating applicator system may be switched from the unlocked state back to the locked state.

Techniques are provided for controlling delivery of a therapeutic coating to a medical implant device. An identifier of the medical implant device may be received. It may be determined, based at least in part on the first identifier, that the first medical implant device is approved to receive the therapeutic coating. A coating applicator system may be switched from a locked state in which it is prohibited from applying the therapeutic coating to an unlocked state in which it is permitted to apply the therapeutic coating. The coating applicator system may, while in the unlocked state, apply the therapeutic coating to the first medical implant device. After the applying of the therapeutic coating, the coating applicator system may be switched from the unlocked state back to the locked state.

An implantable medical device includes a polymer substrate and at least one nanofiber. The polymer substrate includes a surface portion extending into the polymer substrate from a surface of the substrate. The at least one nanofiber includes a first portion and a second portion. The first portion is interpenetrated with the surface portion of the substrate, and mechanically fixed to the substrate. The second portion projects from the surface of the substrate.